11(top 5%)
papers
769(top 2%)
citations
9(top 2%)
h-index
9(top 5%)
g-index
12
all documents
820
doc citations
322
citing journals

Top Articles

#TitleJournalYearCitations
1Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant MelanomaJournal of Biological Chemistry2012171
2LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent MechanismsMolecular Cancer Therapeutics2015144
3The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 UpregulationMolecular Cancer Therapeutics2014126
4Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3PLoS ONE201583
5Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast CancerMolecular Cancer Therapeutics201877
6LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancerOncotarget201756
7Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patientsScientific Reports201954
8PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in MelanomaPLoS Genetics201641
9Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS MutationsClinical Cancer Research201740
10Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers201527
11Abstract 2828: Preclinical activity of abemaciclib as a single agent or in combination with anti-mitotic or targeted therapies for breast cancer20160